Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Yland JJ, McKinnon CJ, Hatch EE, Eisenberg ML, Nillni YI, Rothman KJ, Wise LA. A prospective study of male depression, psychotropic medication use, and fecundability. Am J Mens Health. 2022 Jan;16(1):155798832. doi: 10.1177/15579883221075520
Akashi-Ronquest N. The impact of biological preferences on parental investments in children and step-children. Rev Econ Househ. 2009 Mar 1;7(1):59-81.
Van Houtven CH, Wilson MR, Clipp EC. Informal care intensity and caregiver drug utilization. Rev Econ Househ. 2005;3(4):415-33.